Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.84
-0.0200-0.52%
Pre-market: 3.850.0100+0.26%04:00 EDT
Volume:786.21K
Turnover:3.01M
Market Cap:120.15M
PE:-0.93
High:3.90
Open:3.90
Low:3.75
Close:3.86
52wk High:50.40
52wk Low:3.60
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.97
T/O Rate:4.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.55
PE(LYR):-1.35

Loading ...

Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI

MT Newswires Live
·
Sep 23

Travere Therapeutics receives notice of allowance for FILSPARI patent

TIPRANKS
·
Sep 23

Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress

GlobeNewswire
·
Sep 23

Cardiol Therapeutics Expands Phase III MAVERIC Trial After Early Enrollment Milestone

TIPRANKS
·
Sep 23

BTIG Initiates Maze Therapeutics at Buy With $50 Price Target

MT Newswires Live
·
Sep 23

Analyst Reiterates Buy on Kazia Therapeutics, Maintaining $40 Price Target as Paxalisib Advances into Rare Epilepsy Trial

TIPRANKS
·
Sep 23

Maze Therapeutics initiated with a Buy at Citi

TIPRANKS
·
Sep 23

Prescient Therapeutics Raises Around AU$4.8 Million Via Share Purchase Plan, AU$1.2 Million in Shortfall Placement

MT Newswires Live
·
Sep 23

Top Executive Makes Significant Move in Structure Therapeutics Stock

TIPRANKS
·
Sep 23

Prescient Therapeutics Plans New Share Placement on ASX

TIPRANKS
·
Sep 23

Press Release: Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release

Dow Jones
·
Sep 23

Decoy Therapeutics Enters Warrant Inducement Deal for $3.85 Million; Shares Rise

MT Newswires Live
·
Sep 23

Maze Therapeutics up over 21%, on Pace for Largest Percent Increase Since September 2025

Dow Jones
·
Sep 23

Summit Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Sep 23

Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says

MT Newswires Live
·
Sep 22

Maze Therapeutics Reiterated Buy as APOL1 Opportunity Expands; $64 Price Target Maintained

TIPRANKS
·
Sep 22

Qyuns Therapeutics Updates Board Composition and Governance Structure

TIPRANKS
·
Sep 22

Qyuns Therapeutics Raises QX001S Deal Caps and Refreshes Board Line-Up

TIPRANKS
·
Sep 22

Viking Therapeutics Surges Nearly 50% Premarket as Once-Every-Two-Week Dosing Retains 97% of Weight Loss

Stock News
·
Sep 22

Quince Therapeutics Raised to Market Outperform from Market Perform by Citizens

Dow Jones
·
Sep 22